At the news
? NEUTRALIMPACT 2/10 6-K filed Jul 1, 2026 at 10:10 ET
AstraZeneca filed a routine 6-K reporting the admission of 14,784 ordinary shares issued under employee share schemes during June 2026. The new shares represent ~0.001% dilution to the 1.55B shares outstanding, immaterial and administrative in nature.
- 14,784 ordinary shares of $0.25 each were admitted to trading on the London Stock Exchange Main Market
- Shares were issued under employee share schemes between June 1 and June 30, 2026
- Total shares outstanding post-admission: 1,551,024,534
- New shares are fully fungible with existing ordinary shares (ISIN: GB0009895292)
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access